Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.96 USD
+0.04 (1.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.89 -0.07 (-2.36%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LSTA 2.96 +0.04(1.37%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
Other News for LSTA
Lisata Therapeutics Q2 2025 Earnings Preview
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
LSTA Shows Promising Results in Latest iLSTA Trial | LSTA Stock News
Lisata Therapeutics (LSTA) Completes Enrollment for Pancreatic Cancer Trial | LSTA Stock News